Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Lung Cancer Treatments and Mutations, Cancer Genomics and Diagnostics, Cancer Immunotherapy and Biomarkers, and Lung Cancer Research Studies.
Supplementary Table S1 from Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer
Supplementary Figure S5 from Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer
Supplementary Figure S8 from Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer
Data from Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer
Supplementary Table S3 from Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer
Supplementary Figure S7 from Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer
Supplementary Figure S1 from Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer
Supplementary Figure S6 from Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer
Supplementary Figure S4 from Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer
Supplementary Table S2 from Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer
Supplementary Figure S2 from Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer
Supplementary Figure S3 from Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer
Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations.
Development and validation of a serum proteomic test for predicting patient outcomes in advanced non-small cell lung cancer treated with atezolizumab or docetaxel
2790P Machine learning classification of small cell lung cancer using plasma multiomics in IMPower133
Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade
Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells
Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T<sub>reg</sub> cells.
Analytical evaluation of circulating tumor DNA sequencing assays
Author Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells
Author Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T<sub>reg</sub> cells.
Publisher Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T<sub>reg</sub> cells.
Publisher Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T<sub>reg</sub> cells.
Publisher Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells
Publisher Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells
A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer
A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer.
Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide
Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non-Small Cell Lung Cancer.
Author Correction: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial